4D Molecular Therapeutics (FDMT) Capital Expenditures Growth (1y) (2021 - 2025)
4D Molecular Therapeutics (FDMT) Capital Expenditures Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -27.93% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 355.32% |
| Sep 30, 2025 | -105.12% |
| Jun 30, 2025 | 59.60% |
| Mar 31, 2025 | -80.28% |
| Dec 31, 2024 | 147.74% |
| Sep 30, 2024 | -6.91% |
| Jun 30, 2024 | 149.86% |
| Mar 31, 2024 | -29.84% |
| Dec 31, 2023 | -351.82% |
| Sep 30, 2023 | 123.79% |
| Jun 30, 2023 | -133.88% |
| Mar 31, 2023 | -84.22% |
| Dec 31, 2022 | -108.63% |
| Sep 30, 2022 | -318.93% |
| Jun 30, 2022 | 922.77% |
| Mar 31, 2022 | 4,322.76% |
| Sep 30, 2021 | 1,067.55% |
| Jun 30, 2021 | -30.34% |
| Mar 31, 2021 | 935.71% |